Atara Biotherapeutics Income Statement (2022-2025) | ATRA

Income Statement Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 7.31M51.58M4.46M0.22M1.23M0.96M2.14M4.25M27.36M28.64M40.19M32.75M98.15M17.57M3.45M
Cost of Revenue 0.22M2.90M2.62M3.16M1.99M4.63M7.60M6.79M20.44M0.55M0.12M
Gross Profit 7.31M51.58M4.46M0.22M1.01M-1.94M-0.48M1.09M25.37M24.01M32.59M25.96M77.71M17.02M3.34M
Operating items
Research & Development 74.96M64.90M70.16M62.52M62.16M56.14M56.89M49.60M45.51M33.33M43.92M28.72M27.43M7.31M2.92M
Selling, General & Administrative 20.57M18.81M18.92M13.24M13.87M13.34M12.25M11.45M11.11M8.91M10.42M9.44M11.47M6.51M3.99M
Other Operating Expenses 50.24M0.22M1.99M4.63M7.60M6.79M20.44M0.55M0.12M
Operating Expenses 95.53M83.71M89.08M75.76M76.24M72.37M71.75M64.21M58.60M46.87M61.95M44.96M59.35M14.38M7.03M
Operating Income -88.22M-32.13M-84.62M-75.54M-75.02M-71.41M-69.61M-59.96M-31.25M-18.23M-21.76M-12.20M38.80M3.20M-3.57M
EBIT -88.22M-32.13M-84.62M-75.54M-75.02M-71.41M-69.61M-59.96M-31.25M-18.23M-21.76M-12.20M38.80M3.20M-3.57M
Non-operating items
Other Non Operating Income -0.11M-0.21M-0.31M-0.07M-0.20M-0.01M-0.03M-0.01M0.07M-0.01M0.56M-0.09M-0.01M0.02M0.00M
Non Operating Income 0.12M50.60M0.54M0.97M0.27M0.31M-0.20M-0.62M-0.48M-0.82M0.56M-0.51M-0.79M-0.81M-0.70M
Net income details
EBT -88.11M18.47M-84.08M-74.67M-74.75M-71.11M-69.82M-60.69M-31.73M-19.05M-21.93M-12.71M38.01M2.39M-4.28M
Tax Provisions 0.01M0.00M0.02M0.00M-0.02M0.01M0.02M-0.02M-0.02M0.00M0.03M
Profit After Tax -88.11M18.47M-84.09M-74.57M-74.77M-71.11M-69.80M-60.45M-31.75M-19.05M-21.91M-12.69M38.01M2.39M-4.30M
Income from Continuing Operations -88.11M18.47M-84.09M-74.68M-74.77M-71.11M-69.80M-60.70M-31.75M-19.05M-21.91M-12.69M38.01M2.39M-4.30M
Consolidated Net Income -88.11M18.47M-84.09M-74.68M-74.77M-71.11M-69.80M-60.70M-31.75M-19.05M-21.91M-12.69M38.01M2.39M-4.30M
Income towards Parent Company -88.11M18.47M-84.09M-74.68M-74.77M-71.11M-69.80M-60.70M-31.75M-19.05M-21.91M-12.69M38.01M2.39M-4.30M
Net Income towards Common Stockholders -88.11M18.47M-84.09M-74.68M-74.77M-71.11M-69.80M-60.70M-31.75M-19.05M-21.91M-12.69M38.01M2.39M-4.30M
Additional items
EPS (Basic) -0.870.18-0.82-0.73-0.72-16.91-16.40-13.92-5.65-3.10-2.93-1.703.530.20-0.32
EPS (Weighted Average and Diluted) -0.870.18-0.82-0.73-0.72-16.91-16.40-13.92-5.65-3.10-2.93-1.703.500.19-0.32
Shares Outstanding (Weighted Average) 100.73M101.60M102.42M101.99M103.97M4.20M4.26M4.24M5.62M6.14M7.47M7.49M10.76M12.20M13.56M
Shares Outstanding (Diluted Average) 100.73M101.87M102.42M101.99M103.97M4.20M4.26M4.24M5.62M6.14M7.47M7.49M10.85M12.31M13.56M
EBITDA -89.63M17.74M-84.43M-73.68M-73.94M-70.80M-69.44M-60.08M-31.60M-19.01M-21.87M-12.71M38.00M2.39M-4.30M
Interest Expenses 0.00M0.13M0.12M0.12M1.34M1.38M1.40M1.18M1.15M1.26M1.18M1.02M1.02M0.97M0.91M
Tax Rate -0.01%0.00%-0.03%0.00%0.03%-0.02%-0.08%0.08%0.15%0.13%-0.65%